Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin

Vaccine

Volumn 23, Issue 39, 2005, Pages 4775-4784

  Smallshaw, Joan E ^a   Richardson, James A ^b   Pincus, Seth ^c   Schindler, John ^a   Vitetta, Ellen S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Bioterrorism; Ricin; RiVax; Vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; RIBOSOME INACTIVATING PROTEIN; RICIN; RICIN A; RIVAX; UNCLASSIFIED DRUG; ANTIBODY; ANTISERUM; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL WARFARE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; FEMALE; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VACCINATION; ANIMAL; BLOOD; IMMUNOLOGY; RABBIT;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; FEMALE; IMMUNE SERA; MALE; MICE; RABBITS; RECOMBINANT PROTEINS; RICIN; VACCINES, SYNTHETIC;

EID: 25144493280     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.04.037     Document Type: Article

References (23)

1. Lord JM, Roberts LM, Robertus JD. Ricin: structure, mode of action and some current applications. FASEB J 1994;8:201-8.
2. Eiklid K, Olsnes S, Pihl A. Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp Cell Res 1980;126:321-6.
3. Franz DR, Jaax NK. Ricin toxin. In: Zajtchuk R, Bellamy RF, editors. Textbook of Military Medicine. 1997. p. 631-42.
4. Crampton R, Gall D. Georgi Markov death in a pellet. Med Leg J 1980;48:51-62.
5. Hewetson JF, Rivera VR, Lemley PV, Pitt ML, Creasia DA, Thompson WL. A formalinized toxoid for protection of mice with inhaled ricin. Vaccine Res 1995;4:179-87.
6. Lemley PV, Wright DC. Mice are actively immunized after passive monoclonal antibody prophylaxis and ricin toxin challenge. Immunology 1992;76(3):511-3.
7. Lemley PV, Amanatides P, Wright DC. Identification and characterization of a monoclonal antibody that neutralizes ricin toxicity in vitro and in vivo. Hybridoma 1994;13:417-21.
8. Hewetson JF, Assaad A, Teters DR, Kotes JM, Washington E, Tammariello R, et al. Immune response and protection of rats and mice from ricin aerosol exposure after vaccination with deglycosylated ricin A chain (Abstract). Fundam Appl Toxicol 1996;30(Suppl.): 59.
9. Thorpe PE, Detre SI, Foxwell BMJ, Brown ANF, Skilleter DN, Wilson, et al. Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures Effects on toxicity and in vivo distribution. Eur J Biochem 1985;147:197-206.
10. Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, et al. A phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 1991;51:4052-8.
11. Olson MA. Ricin A-chain structural determinant for binding substrates analogues: a molecular dynamics simulation analysis. Proteins 1997;27:80-95.
12. Kim Y, Robertus JD. Analysis of several key active site residues of ricin-A-chain by mutagenesis and X-ray crystallography. Protein Eng 1992;8:775-9.
13. Ready MP, Kim YS, Robertas JD. Site-directed mutagenesis of ricin-A-chain and implications for the mechanism of action. Protein-Struct Funct Genet 1991;10:270-8.
14. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci USA 1999;96:3957-62.
15. Smallshaw JE, Firan A, Fulmer JR, Ruback SL, Ghetie V, Vitetta ES. A novel recombinant vaccine which protects mice against ricin intoxication. Vaccine 2002;20:3422-7.
16. O'Hare M, Brown AN, Hussain K, Gebhardt A, Watson G, Roberts LM, et al. Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence. FEBS Lett 1990;273:200-4.
17. Simpson JC, Lord JM, Roberts LM. Point mutations in the hydrophobic C-terminal region of ricin A chain indicate that Pro250 plays a key role in membrane translocation. Eur J Biochem 1995;232:458-63.
18. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual Cold Spring Harbor. 2nd ed. Cold Spring Harbor Laboratory; 1989.
19. Press OW, Vitetta ES, Farr AG, Hansen JA, Martin PJ. Evaluation of ricin A-chain immunotoxins directed against human T cells. Cell Immunol 1986;102:10-20.
20. Puri RK, Rosenberg SA. Combined effects of interferon alpha and interleukin 2 on the induction of a vascular leak syndrome in mice. Cancer Immunol Immunother 1989;28:267-74.
21. Maddaloni M, Cooke C, Wilkinson R, Stout AV, Eng L, Pincus SH. Immunological characteristics associated with protective efficacy of antibodies to ricin. J Immunol 2004;172:6221-8.
22. Chanh TC, Hewetson JF. Polyclonal anti-idiotypes induce antibody responses protective against ricin cytotoxicity. Immunology 1993;79(4):681-4.
23. Olson MA, Carra JH, Roxas-Duncan V, Wannemacher RW, Smith LA, Millard CB. Finding a new vaccine in the ricin protein fold. Protein Eng Design Select 2004;17:391-7.